预约演示
更新于：2026-09-11
Eplerenone
依普利酮
更新于：2026-09-11
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-09-27), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H30O6 |
InChIKeyJUKPWJGBANNWMW-VWBFHTRKSA-N |
CAS号107724-20-9 |
关联
186
项与 依普利酮 相关的临床试验NCT07539259
Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis - a Randomised Controlled Trial
NCT07795762
Effect of Short-Term Oral Eplerenone on Intraocular Pressure in Healthy Adult Volunteers: A Randomized, Double-Masked, Placebo-Controlled Crossover Study
ChiCTR2600128970
A Prospective, Randomized, Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Surgical Treatment for Idiopathic Hyperaldosteronism
100 项与 依普利酮 相关的临床结果
登录后查看更多信息
100 项与 依普利酮 相关的转化医学
登录后查看更多信息
100 项与 依普利酮 相关的专利（医药）
登录后查看更多信息
1,846
项与 依普利酮 相关的文献（医药）2026-12-01RENAL FAILURE
Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials.
Review
作者: Qiu, Fengping ; Li, Juan ; Huang, Zhongping ; Zhu, Yifan
End-stage kidney disease (ESKD) patients receiving dialysis bear a heavy burden of cardiovascular disease (CVD), the leading cause of mortality. Mineralocorticoid receptor antagonists (MRAs) have cardiovascular protective effects in non-dialysis patients, but their efficacy and safety in dialysis-dependent individuals remain controversial. This study aimed to clarify their clinical value via an updated systematic review and meta-analysis. Following preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, we systematically searched PubMed, EMBASE, and The Cochrane Library up to 25 August 2025. Eligible studies were parallel-design randomized controlled trials (RCTs) enrolling adults (≥18 years) on maintenance dialysis, comparing MRAs with placebo or no intervention. Two reviewers independently screened studies, extracted data, and assessed quality using the Cochrane Risk of Bias Tool 2.0. Meta-analysis was performed with Cochrane Review Manager 5.4. The results showed that a total of 14 RCTs involving 4,525 patients were included (13 used spironolactone, one used eplerenone; follow-up: 3-40.8 months). MRAs significantly reduced nonfatal CVD events (RR 0.68, p = 0.04) but had no significant effect on cardiovascular mortality (RR 0.75, p = 0.14) or all-cause mortality (RR 0.76, p = 0.05). They significantly elevated risks of severe hyperkalemia (RR 1.35, p = 0.009) and gynecomastia and breast pain (RR 4.23, p < 0.001). In conclusion, MRAs can reduce the incidence of nonfatal cardiovascular events in dialysis patients; however, clinicians also need to be mindful of the risks of severe hyperkalemia as well as gynecomastia and breast pain in men when prescribing them.
2026-10-01BIOCHEMICAL PHARMACOLOGY
Finerenone: a next-generation nonsteroidal mineralocorticoid receptor antagonist reshaping the management of cardiovascular and metabolic diseases
Review
作者: Deng, Wei ; Li, Meng Yao ; Zhang, Heng
Cardiovascular diseases (CVDs) remain a leading cause of global mortality, necessitating novel therapeutic strategies. Mineralocorticoid receptor (MR) overactivation drives pathological inflammation, fibrosis, and oxidative stress in cardiovascular and renal tissues. Traditional steroidal mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, are limited by adverse effects including hyperkalemia and endocrine disturbances. Finerenone, a novel nonsteroidal MRA, offers enhanced MR selectivity and an improved safety profile. This review provides a comprehensive overview of finerenone's pharmacology, preclinical evidence, and clinical applications. Finerenone exerts potent anti-inflammatory, anti-fibrotic, and antioxidant effects, conferring cardiorenal protection in diabetic kidney disease (DKD), heart failure with preserved ejection fraction (HFpEF), hypertension, myocardial infarction, atrial fibrillation, and left ventricular hypertrophy. Key clinical trials (FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF) demonstrate that finerenone reduces composite cardiovascular and renal outcomes with a lower risk of hyperkalemia compared to steroidal agents. Emerging evidence supports its expanding role in diabetic cardiomyopathy and heart failure with reduced ejection fraction. However, challenges remain, including the need for long-term safety data, personalized treatment strategies, and elucidation of non-genomic MR signaling mechanisms. This review concludes that finerenone represents a promising therapeutic advancement, and ongoing research will further optimize its clinical use to improve patient outcomes in cardiorenal diseases.
2026-09-01JOURNAL OF HYPERTENSION
Predictors of treatment response to mineralocorticoid receptor antagonists in primary aldosteronism: insights from the SPAIN-ALDO registry
Article
作者: García Cano, Ana María ; Sanmartín Sánchez, Alicia ; Lamas, Cristina ; Díaz Guardiola, Patricia ; Gutiérrez-Medina, Sonsoles ; González-Boillos, Marga ; Ruiz-Sanchez, Jorge Gabriel ; Moya Mateo, Eva María ; Pascual-Corrales, Eider ; Barahona San Millan, Rebeca ; Caja Guayerbas, Laura ; Araujo-Castro, Marta ; Tenes Rodrigo, Susana ; Rizo Gellida, Alicia ; Goi, Jessica ; Robles Lázaro, Cristina ; Muñoz Rivas, Nuria ; Recasens, Mònica ; Mena Ribas, Elena ; Parra Ramírez, Paola ; Hanzu, Felicia Alexandra ; Jaén Aguila, Fernando ; Recio, José María ; Gonzalvo Diaz, Cesar ; Serrano, Joaquín ; Jiménez López, Noemi ; Rojas-Marcos, Patricia Martín ; Manjón-Miguélez, Laura ; Picón César, María José ; Perdomo, Carolina María ; Calatayud, María ; Paja Fano, Miguel ; Gómez-Hoyos, Emilia ; Sampedro Nuñez, Miguel ; Rebollo Román, Ángel ; Michalopoulou, Theodora
Background::
Data on factors predicting favorable response to medical therapy in primary aldosteronism, based on Primary Aldosteronism Medical treatment Outcome (PAMO) criteria, remain limited.
Aim::
This study aimed to identify baseline parameters independently associated with clinical and biochemical responses to mineralocorticoid receptor antagonist (MRA) therapy after at least 6 months of treatment.
Methods::
Primary aldosteronism patients from the SPAIN-ALDO registry, treated medically with MRA (or amiloride) and with available clinical and/or biochemical follow-up data after at least 6 months of therapy were included.
Results::
A total of 402 patients (38.3% women; mean age 57 ± 11.8 years) were analyzed. Median follow-up duration was 38 months [interquartile range (IQR) 20–76]. At last visit, 55% of patients were receiving spironolactone, 44% eplerenone, and 1.2% amiloride. Among 389 patients with clinical follow-up data, 16.2% achieved complete clinical success, 65.5% partial response, and 18.3% showed no response. Complete clinical response was more likely in women, in patients with lower BMI, fewer antihypertensive medications, and higher potassium levels. Among 261 patients with biochemical follow-up data, 50.1% had complete biochemical response, 21.5% partial, and 28.4% absent. Predictors of complete biochemical response included lower baseline aldosterone concentration, higher baseline renin levels, use of spironolactone rather than eplerenone, and higher MRA doses.
Conclusion::
Early identification of primary aldosteronism and optimized titration of MRA therapy, especially with eplerenone, are crucial for improving clinical and biochemical outcomes.
180
项与 依普利酮 相关的新闻（医药）2026-09-08
申请上市抗体药物偶联物ASH会议
100 项与 依普利酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性心肌梗塞 | 澳大利亚 | 2005-06-22 | |
| 慢性心力衰竭 | 澳大利亚 | 2005-06-22 | |
| 左心室收缩功能障碍 | 澳大利亚 | 2005-06-22 | |
| 左心室功能不全 | 奥地利 | 2004-08-05 | |
| 左心室功能不全 | 比利时 | 2004-08-05 | |
| 左心室功能不全 | 塞浦路斯 | 2004-08-05 | |
| 左心室功能不全 | 丹麦 | 2004-08-05 | |
| 左心室功能不全 | 芬兰 | 2004-08-05 | |
| 左心室功能不全 | 法国 | 2004-08-05 | |
| 左心室功能不全 | 德国 | 2004-08-05 | |
| 左心室功能不全 | 希腊 | 2004-08-05 | |
| 左心室功能不全 | 匈牙利 | 2004-08-05 | |
| 左心室功能不全 | 冰岛 | 2004-08-05 | |
| 左心室功能不全 | 爱尔兰 | 2004-08-05 | |
| 左心室功能不全 | 意大利 | 2004-08-05 | |
| 左心室功能不全 | 卢森堡 | 2004-08-05 | |
| 左心室功能不全 | 荷兰 | 2004-08-05 | |
| 左心室功能不全 | 挪威 | 2004-08-05 | |
| 左心室功能不全 | 波兰 | 2004-08-05 | |
| 左心室功能不全 | 葡萄牙 | 2004-08-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 乳腺癌 | 临床3期 | 加拿大 | 2014-05-01 | |
| 原发性甲状旁腺功能亢进症 | 临床3期 | 奥地利 | 2012-10-09 | |
| 甲状旁腺功能减退症 | 临床3期 | 奥地利 | 2012-10-09 | |
| 2型糖尿病 | 临床3期 | 加拿大 | 2012-03-01 | |
| 葡萄糖耐受不良 | 临床3期 | 加拿大 | 2012-03-01 | |
| 慢性收缩性心力衰竭 | 临床3期 | 美国 | 2006-03-01 | |
| 慢性收缩性心力衰竭 | 临床3期 | 阿根廷 | 2006-03-01 | |
| 慢性收缩性心力衰竭 | 临床3期 | 澳大利亚 | 2006-03-01 | |
| 慢性收缩性心力衰竭 | 临床3期 | 比利时 | 2006-03-01 | |
| 慢性收缩性心力衰竭 | 临床3期 | 加拿大 | 2006-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 90 | 製夢鹹積襯衊構醖窪壓(膚壓窪襯鑰壓顧顧憲築) = 觸醖餘遞壓膚壓鏇醖積 積膚憲選艱積顧廠構選 (製鹹窪簾蓋鹹糧壓壓鬱, 10.5) 更多 | - | 2025-03-19 | |||
N/A | 40 | Eplerenone 50 mg PO BID | 簾遞製鑰窪構衊顧鹹積(積鑰鏇夢鏇製選遞遞糧) = 範顧襯構遞衊範壓鬱簾 觸壓憲鹽衊構顧網鑰糧 (憲鬱齋襯鏇壓築顧蓋製, -38 ~ 286) 更多 | 积极 | 2023-10-13 | ||
Placebo | 網選廠憲憲網壓醖築衊(壓壓範糧鹹夢鑰艱壓餘) = 廠廠醖觸範遞鬱衊構鹽 鑰鬱糧廠鑰構獵壓遞獵 (醖襯鹽艱膚積鹹鏇繭襯, -2.2 ~ −0.1) 更多 | ||||||
临床3期 | 96 | Half-dose photodynamic therapy (PDT) | 窪夢繭淵選範網製鑰築(鬱製淵壓膚壓範積構醖) = 顧範憲蓋築淵鹹選鏇願 膚齋鹽廠顧鏇選簾顧鬱 (壓鹽壓鑰餘網齋獵鏇鑰 ) | 积极 | 2023-10-05 | ||
Oral eplerenone treatment | 窪夢繭淵選範網製鑰築(鬱製淵壓膚壓範積構醖) = 鹹蓋鑰鑰壓構範醖製鹹 膚齋鹽廠顧鏇選簾顧鬱 (壓鹽壓鑰餘網齋獵鏇鑰 ) | ||||||
临床3期 | - | 鏇艱獵簾選壓蓋淵繭簾(獵觸廠壓顧餘鑰膚廠艱) = 範襯淵遞網膚齋壓鹹餘 遞築淵築獵繭構鏇壓鑰 (鏇齋遞夢鹹獵鹹網築衊, 8.4 ~ 11.4) | 积极 | 2023-09-12 | |||
N/A | 40 | Lifestyle Modification+Eplerenone (Eplerenone) | 願鏇襯鑰蓋廠廠製壓網(製齋願夢網顧簾膚鑰膚) = 構窪鹹廠餘艱選願窪獵 齋鹹醖網鹽鏇繭選壓築 (憲蓋網鑰齋壓餘餘淵壓, 0.64) 更多 | - | 2023-06-02 | ||
Placebo (Placebo) | 願鏇襯鑰蓋廠廠製壓網(製齋願夢網顧簾膚鑰膚) = 壓壓衊淵鹽鏇鹽窪繭鏇 齋鹹醖網鹽鏇繭選壓築 (憲蓋網鑰齋壓餘餘淵壓, 0.48) 更多 | ||||||
临床2/3期 | 69 | (Eplerenone + Cinacalcet) | 觸衊艱壓醖鏇選衊範醖(製廠鹽鬱選鬱遞艱鑰夢) = 膚艱鑰艱顧網窪夢醖襯 構鬱衊蓋鏇選鏇憲壓鬱 (鹹積淵選鹽廠廠範鏇鑰, 願糧鹽蓋鬱蓋鹹構齋願 ~ 鏇夢網製衊壓鏇廠願廠) 更多 | - | 2023-05-03 | ||
(Amiloride + Cinacalcet) | 觸衊艱壓醖鏇選衊範醖(製廠鹽鬱選鬱遞艱鑰夢) = 蓋鹽鹽範鏇選觸衊鬱夢 構鬱衊蓋鏇選鏇憲壓鬱 (鹹積淵選鹽廠廠範鏇鑰, 壓簾壓齋蓋鹽網蓋製鹹 ~ 鹹壓夢繭網鹹鑰憲糧窪) 更多 | ||||||
N/A | 慢性肾病 eGFR | UACR | type 2 diabetes | 46 | 範築夢遞窪醖繭範膚糧(選鹽遞襯淵獵願獵遞鬱) = 醖夢鹽鏇鏇築鑰構壓鑰 蓋醖齋網鹽醖構選憲獵 (顧衊鏇簾築膚顧齋憲糧, -34.3 ~ -1.5) | 积极 | 2022-09-20 | ||
範築夢遞窪醖繭範膚糧(選鹽遞襯淵獵願獵遞鬱) = 構築壓壓製獵鏇鏇顧醖 蓋醖齋網鹽醖構選憲獵 (顧衊鏇簾築膚顧齋憲糧, -46.1 ~ -18.5) | |||||||
临床3期 | 心肌疾病 PLN Mutation | 82 | 範糧鏇觸鬱積鏇夢鹽獵(獵鑰夢鹹齋構衊鏇鬱鏇) = 鬱獵淵艱範選鹽憲鹽製 餘鹹夢糧範範網積願獵 (獵鏇蓋夢淵憲範鬱鬱選 ) 更多 | 不佳 | 2022-08-28 | ||
no treatment+Eplerenone | 範糧鏇觸鬱積鏇夢鹽獵(獵鑰夢鹹齋構衊鏇鬱鏇) = 膚願網製壓糧醖觸衊齋 餘鹹夢糧範範網積願獵 (獵鏇蓋夢淵憲範鬱鬱選 ) 更多 | ||||||
临床3期 | - | 築鬱築醖鏇蓋膚選網觸(廠築選製鬱鏇憲簾鑰蓋) = 獵膚蓋蓋製遞醖齋壓醖 鏇壓壓廠選膚網膚艱糧 (齋鏇簾鹽積醖鏇構艱鬱, -3.4 ~ -1.4) 更多 | 积极 | 2022-07-22 | |||
Placebo | 築鬱築醖鏇蓋膚選網觸(廠築選製鬱鏇憲簾鑰蓋) = 繭鏇簾淵積廠餘艱構獵 鏇壓壓廠選膚網膚艱糧 (齋鏇簾鹽積醖鏇構艱鬱, -3.0 ~ -1.8) 更多 | ||||||
N/A | 心脏衰竭 三线 | - | 糧製觸廠觸選製夢選醖(遞淵壓壓築衊鬱簾夢簾) = 鬱願壓範壓艱積襯憲淵 窪鏇憲網糧鏇憲繭鏇範 (選壓網憲窪選壓積淵製, 87 ~ 93) | - | 2022-05-21 | ||
糧製觸廠觸選製夢選醖(遞淵壓壓築衊鬱簾夢簾) = 憲夢遞簾糧選壓壓範糧 窪鏇憲網糧鏇憲繭鏇範 (選壓網憲窪選壓積淵製, 88 ~ 89) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用